ABUS NASDAQ
Arbutus Biopharma Corp
1W: -8.2%
1M: -12.8%
3M: -10.5%
YTD: -6.7%
1Y: -3.0%
3Y: +121.4%
5Y: -3.7%
$4.45
-0.11 (-2.41%)
Weekly Expected Move ±3.6%
$4
$4
$4
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (34)
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5.3% – Here’s What Happened
Arbutus gains on plans to buy back 46M shares in tender offer
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 130,023 Arbutus Biopharma Corporation $ABUS
Bank of America Corp DE Has $7.58 Million Stock Position in Arbutus Biopharma Corporation $ABUS
Arbutus Biopharma (NASDAQ:ABUS) Reaches New 1-Year High – What’s Next?
Arbutus to repurchase up to $230M of shares in tender offer
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?
MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average – Here’s What Happened
Pfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine tech
Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Moderna's Revenues See Strong International Momentum in Q1 Earnings
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average – Here’s What Happened
ABUS Arbutus Biopharma Corporation beats fourth quarter 2025 earnings estimates, shares rise nearly three percent on soaring year over year revenue. - Annual Summary - Cổng thông tin điện tử Tỉnh Sơn La
Europe Clears First Flu/COVID Combo Shot From Moderna
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability
QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving Average – What’s Next?
Arbutus Biopharma GAAP EPS of -$0.17 misses by $0.13, revenue of $14.08M beats by $13.47M
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation $ABUS Shares Sold by Hudson Bay Capital Management LP
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving Average – Here’s Why
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
Moderna gains as Arbutus/ Genevant settlement removes major financial risk
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
Staar Surgical Posts Downbeat Q4 Results, Joins Webtoon Entertainment, Gitlab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Moderna surges after hours on patent settlement with Arbutus and Genevant
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know